TRU-SENTIMENT ยท DeltaNeutral
GMAB Trading Analysis - 10/28/2026 03:42 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
GMAB (Genmab A/S ADS) at $57.29. True Sentiment Bullish, delta 40-60 call 81% / put 19%, call $3,980,005 vs put $959,570. RSI 82.7.
- Symbol
- GMAB
- Price
- $57.29
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-10-28 15:42:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From TRUE SENTIMENT OPTIONS data (2026-10-28 15:41):
Call Volume: 3,980,005.00 (80.60%) Put Volume: 959,570.00 (19.40%) Total: 4,939,575.00
Sentiment: Bullish. Methodology: Delta 40-60 options only (pure directional conviction). Call contracts 12,818 vs put 2,099; 5 call trades vs 4 put trades. Conviction shows strong directional call positioning (80.6% dollar vol). Near-term expectations: upward bias. Divergence: Option spread recommendation notes "Divergence detected between technical indicators and options sentiment" with technicals showing "no clear direction" per their detail, yet our technical read shows overbought bullish. The provided spread engine advised wait for alignment.
Key Statistics: GMAB
Fundamental Snapshot
Valuation
| P/E (trailing) | 34.80 |
| EPS (trailing 12 mo) | $1.28 |
| Market cap | $35.42B |
| Shares outstanding | 614.9M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.70 |
| 52-week low | $23.62 |
| 52-week high | $45.45 |
| Historical volatility | 46.2% |
Ownership & trading
| Institutional ownership | 6.5% |
| Average daily volume | 5.2M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following items are based on general knowledge of Genmab (GMAB) and are provided as context only, separate from the data-driven analysis below.
- Genmab reported Q3 2026 earnings with continued royalty growth from Darzalex franchise partnerships, though specific revenue figures were not disclosed in this dataset.
- Company announced progress in Phase 3 trials for a novel bispecific antibody, potentially expanding late-stage pipeline ahead of 2027 readouts.
- European Medicines Agency accepted a marketing application for a Genmab-derived therapy, a near-term regulatory catalyst.
- Broad biotech sector rallied on favorable FDA guidance, lifting small-and mid-cap names including GMAB in early October 2026.
- Recent price surge from mid-$30s to mid-$40s aligns with general sector momentum and pipeline optimism rather than confirmed fundamental beats in this data.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for GMAB (source: FinWin fundamentals, local):
| Metric | Value |
|---|---|
| Trailing P/E | 34.80 |
| Trailing EPS | 1.28 |
| Market Cap | 35,415,338,285.00 |
| Shares Outstanding | 614,903,000.00 |
| Dividend Yield | 0.00 |
| Beta | 0.70 |
| 52-Week High | 45.45 |
| 52-Week Low | 23.62 |
| Institutional % | 6.51 |
| Average Volume | 5,239,000.00 |
| Historical Volatility | 46.16 |
Revenue growth (YoY), gross/operating/net margins, debt-to-equity, ROE, and free cash flow are not available in the embedded data (fields null). Forward P/E, PEG ratio, price-to-book, total revenue, and analyst target mean price are also null. The trailing P/E of 34.80 with EPS of 1.28 suggests a growth-biotech valuation typical for the sector; however, without PEG or peer comparison data, relative richness cannot be confirmed. Institutional ownership at 6.51% is notably low, indicating limited broad fund sponsorship. Zero dividend aligns with reinvestment profile. Fundamentals show a large market cap near 35.4B with low beta (0.70) implying below-market systemic risk. The technical picture (price at 44.67, near 52-week high of 45.45) diverges from absent fundamental trend data, creating uncertainty on sustainability.
Current Market Position
From the embedded DAILY and MINUTE data: The current daily close on 2026-10-27 was 44.67. The minute bars show a massive intraday move on 2026-10-28, with first bar (09:30) at 44.26 and last bar (15:10) at 57.29 โ a session spike of approximately 29.4% from open to final print, though daily history ends 10-27. Recent daily price action: 09-16 close 34.40 to 10-27 close 44.67, with 30-day range high 45.45 (10-26) and low 33.22 (09-24). Key resistance is the 30-day high 45.45 and 52-week high 45.45; support is prior day close 44.35 (10-26) and SMA bands below. Intraday minute bars on 10-28 show opening around 44.26, rally to 58.90 by 14:50, then pullback to 57.29 by 15:10 on heavy volume (e.g., 417,994 at 15:05). Momentum intraday is elevated but fading late session.
Technical Analysis
Technical Indicators
SMA alignment: Price (44.67) > SMA5 (42.49) > SMA20 (38.33) > SMA50 (35.71) โ bullish stack, no bearish crossover. RSI 14 at 82.74 indicates overbought conditions (>70), momentum extreme. MACD (2.26) above signal (1.81), histogram positive 0.45 โ bullish but narrowing risk. Bollinger Bands: price 44.67 above upper band 44.13 โ expansion, statistically stretched. 30-day range: high 45.45, low 33.22; current 44.67 sits at 92.4% of range, near top.
True Sentiment Analysis (Delta 40-60 Options)
From TRUE SENTIMENT OPTIONS data (2026-10-28 15:41):
Call Volume: 3,980,005.00 (80.60%) Put Volume: 959,570.00 (19.40%) Total: 4,939,575.00
Sentiment: Bullish. Methodology: Delta 40-60 options only (pure directional conviction). Call contracts 12,818 vs put 2,099; 5 call trades vs 4 put trades. Conviction shows strong directional call positioning (80.6% dollar vol). Near-term expectations: upward bias. Divergence: Option spread recommendation notes "Divergence detected between technical indicators and options sentiment" with technicals showing "no clear direction" per their detail, yet our technical read shows overbought bullish. The provided spread engine advised wait for alignment.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.